JP2024542633A5 - - Google Patents
Info
- Publication number
- JP2024542633A5 JP2024542633A5 JP2024532158A JP2024532158A JP2024542633A5 JP 2024542633 A5 JP2024542633 A5 JP 2024542633A5 JP 2024532158 A JP2024532158 A JP 2024532158A JP 2024532158 A JP2024532158 A JP 2024532158A JP 2024542633 A5 JP2024542633 A5 JP 2024542633A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- bid
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285320P | 2021-12-02 | 2021-12-02 | |
| US63/285,320 | 2021-12-02 | ||
| US202263382346P | 2022-11-04 | 2022-11-04 | |
| US63/382,346 | 2022-11-04 | ||
| US202263383969P | 2022-11-16 | 2022-11-16 | |
| US63/383,969 | 2022-11-16 | ||
| PCT/IB2022/061525 WO2023100070A1 (en) | 2021-12-02 | 2022-11-29 | Cdk4 inhibitor for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542633A JP2024542633A (ja) | 2024-11-15 |
| JP2024542633A5 true JP2024542633A5 (https=) | 2025-11-19 |
Family
ID=84440018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532158A Pending JP2024542633A (ja) | 2021-12-02 | 2022-11-29 | がん治療用ｃｄｋ４阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250041298A1 (https=) |
| EP (1) | EP4440576A1 (https=) |
| JP (1) | JP2024542633A (https=) |
| KR (1) | KR20240112931A (https=) |
| AU (1) | AU2022400308B2 (https=) |
| CA (1) | CA3240993A1 (https=) |
| IL (1) | IL312650A (https=) |
| MX (1) | MX2024006678A (https=) |
| WO (1) | WO2023100070A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| CN120981721A (zh) | 2023-03-30 | 2025-11-18 | 辉瑞大药厂 | Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法 |
| EP4719405A1 (en) | 2023-06-02 | 2026-04-08 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105828822B (zh) * | 2013-08-14 | 2019-10-18 | 诺华股份有限公司 | 用于治疗癌症的组合疗法 |
| GEP20227433B (en) | 2018-04-26 | 2022-10-25 | Pfizer | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| WO2020157709A1 (en) * | 2019-02-01 | 2020-08-06 | Pfizer Inc. | Combination of a cdk inhibitor and a pim inhibitor |
| FI4181920T3 (fi) * | 2020-07-15 | 2025-11-20 | Pfizer | Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon |
| AU2021325426A1 (en) * | 2020-08-13 | 2023-03-09 | Astellas Pharma Inc. | Combination therapy |
| AU2021345531B2 (en) * | 2020-09-15 | 2024-02-29 | Pfizer Inc. | Solid forms of a CDK4 inhibitor |
| JP2024505680A (ja) * | 2021-02-05 | 2024-02-07 | ベラステム・インコーポレーテッド | 異常な細胞成長を処置するための併用療法 |
-
2022
- 2022-11-29 US US18/714,642 patent/US20250041298A1/en active Pending
- 2022-11-29 KR KR1020247021924A patent/KR20240112931A/ko active Pending
- 2022-11-29 CA CA3240993A patent/CA3240993A1/en active Pending
- 2022-11-29 MX MX2024006678A patent/MX2024006678A/es unknown
- 2022-11-29 AU AU2022400308A patent/AU2022400308B2/en active Active
- 2022-11-29 EP EP22818896.7A patent/EP4440576A1/en active Pending
- 2022-11-29 JP JP2024532158A patent/JP2024542633A/ja active Pending
- 2022-11-29 IL IL312650A patent/IL312650A/en unknown
- 2022-11-29 WO PCT/IB2022/061525 patent/WO2023100070A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024542633A5 (https=) | ||
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| JP2021035955A (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| TW202304424A (zh) | 包含依維莫司和安森司群的組合 | |
| AU2013234767B2 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds | |
| AU2015301097A1 (en) | Drug combinations to treat multiple myeloma | |
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| WO2015185011A1 (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 | |
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| US20140057897A1 (en) | Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias | |
| WO2020072774A1 (en) | Combination therapy for the treatment of uveal melanoma | |
| JP2024520567A (ja) | 肺線維症の予防または治療用の薬学製剤 | |
| JP7357386B2 (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| JP7142707B2 (ja) | ピラゾロ［３，４－ｄ］ピリミジン化合物を有効成分とする治療剤 | |
| US20260014194A1 (en) | Combinations comprising metap2 inhibitors for the treatment of cancer | |
| RU2024114897A (ru) | Ингибитор cdk4 для лечения рака | |
| EP4719405A1 (en) | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer | |
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| TWI922738B (zh) | 化合物或其藥劑學上可接受的鹽用於製造實性瘤治療用醫藥組成物之用途 | |
| HK40110657A (zh) | 用於治疗癌症的cdk4抑制剂 | |
| KR20240159340A (ko) | 폐섬유화 예방 또는 치료를 위한 펙시다티닙 및 닌테다닙의 병용 요법 | |
| WO2026021460A1 (zh) | 治疗前列腺癌的方法 | |
| TW202416992A (zh) | 雌激素受體降解劑之給藥方案 | |
| US20070021432A1 (en) | Treatment of mesothelioma |